I agree that this site is using cookies. You can find further informations here.
X
De Marinis, F.
352  results:
Search for persons X
?
1

27P CNS-progression patterns in patients with EGFR-mutant N..:

Attili, I. ; Corvaja, C. ; Spitaleri, G....
ESMO Open.  9 (2024)  - p. 102606 , 2024
Link: https://doi.org/10.1016/..
 
?
2

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with M..:

Kim, T.M. ; Guarneri, V. ; Jye, V.P....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S94 , 2023
Link: https://doi.org/10.1016/..
 
?
3

92P Predictors, surrogate and patient-reported outcomes in ..:

Bertolaccini, L. ; Mohamed, S. ; Galetta, D....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S94-S95 , 2023
Link: https://doi.org/10.1016/..
 
?
4

OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage..:

Herbst, R.S. ; Wu, Y.-L. ; Grohe, C....
Journal of Thoracic Oncology.  18 (2023)  3 - p. e4 , 2023
Link: https://doi.org/10.1016/..
 
?
5

170P Preliminary results from LUMINANCE: A phase IIIb, sing..:

Reinmuth, N. ; de Marinis, F. ; Leighl, N....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S134 , 2023
Link: https://doi.org/10.1016/..
 
?
6

3P Exploratory efficacy analysis by smoking status in PD-L1..:

Paz-Ares, L. ; García-Campelo, M.R. ; Isla Casado, M.D....
Immuno-Oncology and Technology.  20 (2023)  - p. 100474 , 2023
Link: https://doi.org/10.1016/..
 
?
7

LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (E..:

Reinmuth, N. ; Özgüroğlu, M. ; Leighl, N.B....
Immuno-Oncology and Technology.  20 (2023)  - p. 100692 , 2023
Link: https://doi.org/10.1016/..
 
?
8

OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell S..:

Herbst, R.S. ; Ruderman, D. ; Conway, J....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S79-S80 , 2023
Link: https://doi.org/10.1016/..
 
?
9

EP07.04-06 ALK Rearrangement Is Associated with Early Lymph..:

Gallina, F.T. ; Tajè, R. ; Cecere, F.L....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S545-S546 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic ..:

Spitaleri, G. ; Trillo Aliaga, P. ; Catania, C....
Clinical Lung Cancer.  24 (2023)  1 - p. e19-e26 , 2023
Link: https://doi.org/10.1016/..
 
?
11

P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimer..:

Soo, R. ; De Marinis, F. ; Han, J.-Y....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S272 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Immunotherapy in the first-line treatment of elderly patien..:

Gridelli, C. ; Peters, S. ; Velcheti, V...
ESMO Open.  8 (2023)  2 - p. 101192 , 2023
Link: https://doi.org/10.1016/..
 
?
13

44P Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy..:

Granados, A.L.O. Ortega ; Lim, S.M. ; Schenker, M....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S67-S68 , 2023
Link: https://doi.org/10.1016/..
 
?
14

P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in..:

Landi, L. ; Tiseo, M. ; Heukamp, L.C....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S157 , 2022
Link: https://doi.org/10.1016/..
 
?
15

EP05.03-008 Surgery after First-Line Alectinib for (Locally..:

Lococo, F. ; Chiappetta, M. ; Cancellieri, A....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S297-S298 , 2022
Link: https://doi.org/10.1016/..
 
1-15